Rubella antibody loss rates in Korean children

Epidemiology and Infection

Volumn 129, Issue 3, 2002, Pages 557-564

  Ki, M ^a   Kim, M H ^a   Choi, B Y ^b   Shin, Y J ^b   Park, T ^c  

^a Eulji University School of Medicine   (South Korea)

^b Hanyang University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; RUBELLA ANTIBODY; RUBELLA VACCINE;

ADULT; AGE; ANTIBODY DETECTION; ANTIBODY TITER; CHILD; CONGENITAL RUBELLA SYNDROME; CONTROLLED STUDY; DISEASE CONTROL; FEMALE; FOLLOW UP; GENDER; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREGNANCY; PRIMARY SCHOOL; REVIEW; RUBELLA; STATISTICAL SIGNIFICANCE; STUDENT; TIME; VACCINATION; VIRUS IMMUNITY;

EID: 0036978485     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0950268802007811     Document Type: Review

References (28)

1. Center for Disease Control and Prevention. Measles, mumps, and rubella - vaccine use and strategies for elimination of measles, rubella and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998; 47: 1-57.
2. Asahi T, Ueda K, Hidaka Y, Miyazaki C, Tanaka Y, Nishima S. Twenty-three year follow-up study of rubella antibodies after immunization in a closed population, and serological response to revaccination. Vaccine 1997; 16: 1791-5.
3. Schiff GM, Rauh JL, Young B, Trimble S, Rotte T, Schiff BE. Rubella-vaccinated students, follow-up in a public school system. JAMA 1978; 240: 2635-7.
4. Farquhar JD. Follow-up on rubella vaccinations and experience with subclinical reinfection. J Pediatr 1972; 81: 460-5.
5. Chu SY, Bernier RH, Stewart JA, et al. Rubella antibody persistence after immunization: sixteen-year follow-up in the Hawaiian Islands. JAMA 1988; 259: 3133-6.
6. Boulianne N, Serres GD, Ratnam S, Ward BJ, Joly JR, Duval B. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination. Vaccine 1995; 13: 1611-6.
7. Hermann KL, Halstead SB, Wiebenga NH. Rubella antibody persistence after immunization. JAMA 1982; 247: 193-6.
8. Balfour HH Jr, Groth KE, Edelman CK. RA27/3 Rubella vaccine, a four year follow-up. Am J Dis Child 1980; 134: 350-3.
9. Christenson B, Bottiger M. Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults. Vaccine 1994; 12: 41-5.
10. Davidkin I, Peltola H, Leinikki P, Valle M. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland. Vaccine 2000; 18: 3106-12.
11. O'Shea S, Best JM, Banatvala JE. Viremia, virus excretion, and antibody response after challenge in volunteers with low levels of antibody to rubella virus. J Infect Dis 1983; 148: 639-47.
12. Cusi MG, Rossolini GM, Valensin PE, Cellesi C, Zanchi A. Serological evidence of reinfection among vaccinees during rubella outbreak. Lancet 1990; 336: 1071-3.
13. Cusi MG, Valensin PE, Cellesi C. Possibility of reinfection after immunization with RA 27/3 live attenuated rubella virus. Arch Virol 1993; 129: 337-40.
14. Behrman RE, Kliegman RM, Arvin AM. Nelson textbook of pediatrics, 15th ed. Philadelphia: WB Saunders Co., 1995; 527-8, 871-3.
15. Paludetto R, van dn Heuvel J, Stagni A, Grappone L, Mansi G. Rubella embryopathy after maternal reinfection. Biol Neonate 1994; 65: 340-1.
16. Hornsten L, Levy U, Fogel A. Clinical rubella with transmission to the fetus in a pregnant woman considered to be immune. N Engl J Med 1988; 391: 1415-6.
17. National Institute of Health-Korea. Communicable Diseases Monthly Report 1996; 7: 41.
18. Schaefer LE, Dyke JW, Meglio FD, Murray PR, Crafts W, Niles AC. Evaluation of microparticle enzyme immunoassays for immunoglobulins G and M to rubella virus and Toxoplasma gondii on the Abbott IMx automated analyzer. J Clin Microbiol 1989; 27: 2410-3.
19. Behring. Enzygnosts® Anti-Rubella-Virus/IgG Package Insert, 1998.
20. Skendzel LP. Rubella immunity. Defining the level of protective antibody. AJCP 1996; 106: 170-3.
21. Jennrich RI, Schluchter MD. Unbalanced repeated-measures models with structured covariance matrices. Biometrics 1986; 42: 805-20.
22. Horstmann DM, Schluederberg A, Emmons JE, Evans BK, Randolph MF, Andiman A. Persistence of vaccine-induced immune response to rubella comparison with natural infection. Rev Infect Dis 1985; 7: s80-5.
23. Serdula MK, Halstead SB, Wiebenga NH, Herrmann KL. Serological response to rubella revaccination. JAMA 1984; 251: 1974-7.
24. Ki M, Choi BY, Shin YJ, Park HB, Youn BJ, Han JS. A seroepidemiologic study on rubella antibody in pregnant women in Kyonggi-do. Korean Prevent Med 1997; 30: 279-92.
25. Ki M, Kim MH, Shin YJ, Choi BY. MMR immunization rate and related factors. J Korean Pediatr Soci 2001; 44: 375-88.
26. Weibel RE, Buynak EB, Mclean AA, Hilleman MR. Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccine. Pediatrics 1975; 56: 380-7.
27. Ross R, Harvey DR, Hurley R. Re-infection and congenital rubella syndrome. Practitioner 1992; 236: 246-51.
28. Best JM, Banatvala JE, Morgan-Capner P, Miller E. Fetal infection after maternal reinfection with rubella: criteria defining reinfection. BMJ 1989; 299: 773-5.